Adoptive therapy with monocyte-derived macrophages in the setting of high-dose chemotherapy and peripheral blood stem cell transplantation.
In an attempt to ameliorate chemotherapy-induced side-effects after transplantation of autologous peripheral blood stem cells (PBSCT), we tested the reinfusion of autologous macrophages (MAC) that are known to be potent antimicrobial effector cells and cytokine producers. Ten patients were treated with two sequential cycles of high-dose chemotherapy followed by PBSCT. Before the second cycle of PBSCT, mononuclear cells were harvested, cultured for 8 d in order to induce MAC maturation and reinfused 3 d after PBSCT without clinical problems. However, MAC infusions did not substantially alleviate the toxicity of autologous PBSCT.
Krause
Stefan W
SW
Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany. stefan.krause@klinik.uni-regensburg.de
Gnad
Marcus
M
Reichle
Albrecht
A
Andreesen
Reinhard
R
D019264:Adoptive Transfer / Q000379:methods*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008264:Macrophages / Q000637:transplantation*; D010865:Pilot Projects; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents